Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

Abstract

Contrary to the long held belief that chemotherapy is immunosuppressive, emerging evidence indicates that the anticancer activity of cisplatin is not limited to its ability to inhibit mitosis, but that cisplatin also has important immunomodulatory effects. We therefore methodically examined the relevant preclinical literature and identified four main mechanisms of cisplatin-induced antitumor immunomodulation: (1) MHC class I expression upregulation; (2) recruitment and proliferation of effector cells; (3) upregulation of the lytic activity of cytotoxic effectors; and (4) downregulation of the immunosuppressive microenvironment. Cisplatin-based combination chemotherapy’s antitumor immunomodulatory effects are also beginning to be harnessed in the clinic; we therefore additionally reviewed the applicable clinical literature and discussed how monitoring various components of the immune system (and their responses to cisplatin) can add new levels of sophistication to disease monitoring and prognostication. In summation, this growing body of literature on cisplatin-induced antitumor immunomodulation ultimately highlights the therapeutic potential of synergistic strategies that combine traditional chemotherapy with immunotherapy.

Tumor Infiltrating Lymphocytes-The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer

“…Regardless, the findings from the above analysis are already providing crucial clues for future clinical research. As an example, these studies corroborate pre-clinical work by others suggesting that perhaps some conventional anti-neoplastic drugs such as platinum agents or trastuzumab could induce anti-tumor responses at least in part by modulating the host immune system [13,17,[20][21][22][23]. The finding that high expression of immune checkpoints is associated with lower pCR rates after neo-adjuvant therapy with monoclonal antibodies against HER-2/neu, provides support for studying combinations of trastuzumab and/or pertuzumab and PD1, PDL1 or CTLA-4 inhibitors.…”

Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma

“…This is in concordance with findings in other tumor types, showing that cisplatin promotes recruitment and proliferation of effector immune cells. 36 Future studies with a larger number of samples are required to unravel the best treatment schedule to combine chemotherapy with immunotherapy.…”

Novel Targets for Natural Killer/T-cell Lymphoma Immunotherapy

“…Patients treated with our regimen, known as MPVIC-P (methotrexate, peplomycin, etoposide, ifosfamide and carboplatin), achieved a high rate of complete remission [5]. Recent evidence suggests that platinum-containing chemotherapy has immune-modulating effects such as recruitment of effector CD8 T-cells and downregulation of Treg and MDSC [72].…”